Ramucirumab’s Overall Survival Advantage Disappointing: Analysts

Eli Lilly’s cancer drug ramucirumab achieved a statistically significant but small overall survival advantage in a key gastric cancer trial, underwhelming analysts. But the FDA is still likely to approve the drug without additional Phase III data, one analyst said. Ramucirumab plus best supportive care given as a second-line treatment showed an overall survival benefit of 1.4 months, compared with placebo plus best supportive care in the Phase III REGARD trial.
Clinical Trials Advisor